How a top-performing IPO unraveled under scrutiny (and reshaped my leadership) — with Darryl Baker (EP 010) | Growth Under Pressure

Growth Under Pressure · Dec 15, 2025 · 50m

Fractional CFO Darryl Baker shares how taking Insys Therapeutics public in 2013 and scaling its fentanyl sublingual spray product (Subsys) into over $300M in annual revenue by 2015 collided with DOJ scrutiny, leadership fallout, and bankruptcy. He unpacks what helped him lead through broken trust and personal uncertainty, plus the simple weekly discipline he uses with every client: cash position and a 13-week cash forecast.

—

🌟 Highlights

Why interpersonal "translator" skills matter as much as technical strength for CFO-level leadership

How Darryl thinks AI will amplify finance, but still…